RxDoctor Payments Data

Roland Filart, MD

Clinical Cardiac Electrophysiology · Orlando, FLNPI 1730183781

Payments from drug & device makers

$27,680in general payments, 2019–2025

Across 321 payments — averaging $86.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Abbott$5K
  • Biotronik Inc.$4K
  • Kestra Medical Technology Services, Inc.$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Boston Scientific$1K
  • plus $3K from 20 others

What the payments were for

  • Speaking & faculty fees$2,3008%
  • Travel & lodging$9,55435%
  • Food & beverage$15,77757%
  • Education$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,680 in reported general payments places this provider in the 40th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$553,228
Medicare patients
524
Services billed
4,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban387$456,086
MultaqDronedarone Hcl104$156,533
XareltoRivaroxaban56$77,793
EntrestoSacubitril/Valsartan40$57,914
Dofetilide133$30,382
JardianceEmpagliflozin20$22,994
Ranolazine ErRanolazine90$10,330
Mexiletine Hcl70$9,077
Flecainide Acetate135$5,447
SotalolSotalol Hcl162$4,439
Metoprolol Succinate277$4,045
Midodrine Hcl30$2,977
Bisoprolol Fumarate107$2,450
Amiodarone Hcl96$1,342
Digoxin45$1,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$456,086387 claims
Johnson & JohnsonXarelto$143$77,79356 claims
NovartisEntresto$59$57,91440 claims
Boehringer IngelheimJardiance$104$22,99420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →